Psychedelic-assisted therapy is producing clinical results that dwarf conventional treatments for PTSD, depression, and addiction — using substances that indigenous cultures have used for millennia.
The fortress of psychiatric medicine — SSRIs, benzodiazepines, antipsychotics — is under siege from a class of medicines older than civilization. Psilocybin, MDMA, LSD, and ketamine are producing clinical trial results that the incumbent paradigm cannot explain away: single-dose protocols generating durable remission where decades of daily medication failed.
MDMA-assisted therapy for PTSD showed 71% of participants no longer meeting diagnostic criteria after three sessions — compared to 48% for therapy alone. Psilocybin for treatment-resistant depression demonstrated rapid, sustained response rates that SSRIs cannot match. The mechanisms are fundamentally different: neuroplasticity induction and default mode network disruption rather than chronic symptom suppression.
2026 is the inflection year. MindMed reports Phase 3 data for LSD in generalized anxiety disorder. Compass Pathways reports pivotal data for psilocybin in treatment-resistant depression. Helus reports Phase 3 for psilocybin in major depressive disorder. The Otsuka partnership — a major Japanese pharmaceutical company paying for psychedelic access — signals the credibility threshold has been crossed.
Psychedelic medicine scores 4.6/5.0 — the highest conviction emerging paradigm. The suppression signal is strong, the science is overwhelming, and the 2026 catalyst calendar is loaded. INVEST with conviction.